Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Kono Says Vaccine Rollout Sped Up as Japan Hits 100 Million Dose Mark
August 11, 2021
- Japan to Run Follow-Up Survey for AstraZeneca Vaccine at 6 Hospitals
August 11, 2021
- Prefectural Governors Urge Booster Shot with AstraZeneca Jabs
August 11, 2021
- Lawmakers See No Ultimate Goal in New Pharma Industry Vision
August 6, 2021
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW
August 6, 2021
- Results of Guidelines-Related Studies Can Be Used in Public Knowledge-Based Filings for Fertility Treatments: MHLW
August 6, 2021
- Veklury Distribution via Govt Purchase to Continue for Now: MHLW
August 6, 2021
- Council OKs Public Knowledge-Based Filing for New Indication for Fibrinogen
August 6, 2021
- Industry Sees Overhaul of CEA Scheme “Too Early,” Chuikyo Reps Agree
August 5, 2021
- Chuikyo Calls for Balanced Price-Setting for “Specific-Use” Drugs, Sakigake Products
August 5, 2021
- Ofev Faces 10%-Plus Cut in Quarterly Price Review; Veklury Gets Listing but No Copay for Now
August 5, 2021
- Chuikyo to Compile Proposal on SaMD Reimbursement by Year-End
August 5, 2021
- Up to 580,000 Doses of AstraZeneca’s COVID Vaccine to Be Distributed in Tokyo
August 5, 2021
- August Listing OK’ed for Evrysdi, Veklury, Verquvo, 2 CGRP Migraine Meds and More
August 4, 2021
- Trintellix to Face 4.3% Price Cut under CEA Scheme, No Change for Coralan
August 4, 2021
- Delytact Gets 1.43 Million Yen Price Tag
August 4, 2021
- Temodar Label Revised to Erase Caveat for Combo Cancer Therapy
August 4, 2021
- New Pharma Industry Vision to Push Predictability for Investment Recovery: Draft Outline
August 3, 2021
- MHLW’s COVID-19 Guide Adds Chugai’s Cocktail Therapy
August 3, 2021
- Veklury to Join NHI Price List to Enter Normal Distribution Channel; Peak Sales Put at 18 Billion Yen
August 3, 2021
ページ
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…